Overview

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Status:
Completed
Trial end date:
2019-07-26
Target enrollment:
0
Participant gender:
All
Summary
This is a 4-visit, multi-center, randomized, double-masked, parallel group study evaluating the safety and efficacy of CSF-1 in the treatment of presbyopia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Orasis Pharmaceuticals Ltd.
Criteria
Inclusion Criteria:

- Subjects must:

1. Have presbyopia

Exclusion Criteria:

- Subjects must not:

1. Have any contraindications to the study medications or diagnoses that would
confound the study data